Press releases | Finanzwire

Basculer en Français

11318	Companies
251507	Keywords
180638	Articles
137332	Press releases

Home
Press releases

PRESS RELEASE

published on 04/08/2024 at 23:30, 2 years 7 months ago

Inspire Veterinary Partners Reports Full Year 2023 Financial Results
Inspire Veterinary Partners, Inc. reports approximately 70% revenue growth year-over-year to $16.7M in 2023. Cost reduction initiatives and SG&A savings drive operational efficiency and profitability. Expansion in pet health sector remains promising

Revenue Growth Cost Reduction Initiatives Inspire Veterinary Partners Inc. Pet Health Sector SG&A Savings
PRESS RELEASE

published on 04/08/2024 at 23:25, 2 years 7 months ago

Guanajuato Silver Reports Year End 2023 Financial Results
Guanajuato Silver Company Ltd. announces financial and production results for 2023, showing record production and revenue growth. The Company continues to expand its operations in Mexico

Financial Information Guanajuato Silver Company Ltd. Silver Mines Production Results Record Revenue
PRESS RELEASE

published on 04/08/2024 at 23:20, 2 years 7 months ago

Ur-Energy Announces Appointment of New Board Members: John Paul Pressey and Elmer W. Dyke
Ur-Energy Inc. appoints John Paul Pressey and Elmer W. Dyke as new Board members, announces retirement of James M. Franklin and W. William Boberg. Company expresses gratitude towards retiring Directors

Board Members Ur-Energy Inc. Leadership Transition Retirement Nuclear Power
PRESS RELEASE

published on 04/08/2024 at 23:15, 2 years 7 months ago

Data4Cure Announces a Late-Breaking Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting
Data4Cure announces the release of the Single-Cell Immune Checkpoint Inhibition Atlas at AACR 2024, facilitating insights on cancer immunotherapy. CEO highlights integration of high-throughput data for new therapies

Cancer Research Immunotherapy AACR 2024 Data4Cure Single-cell Atlas
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:12, 2 years 7 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results and business update, highlighting progress in clinical programs and partnerships. CEO Stanislas Veillet shares insights on growth strategies and collaborations

Financial Results Biophytis Partnerships Clinical Programs Growth Strategies
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:10, 2 years 7 months ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA Phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone), aiming to address muscle loss from obesity treatment and promising results in preclinical studies. Clinical study expected to start mid-2024 with results in 2025

Biophytis Clinical Study BIO101 OBA Phase 2 Obesity
PRESS RELEASE

published on 04/08/2024 at 23:04, 2 years 7 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & updates business activities. Successfully developing clinical programmes & obtaining FDA approval for SARA-31 trial in sarcopenia

Biophytis FDA Approval 2023 Financial Results Clinical Programmes SARA-31 Trial
PRESS RELEASE

published on 04/08/2024 at 23:01, 2 years 7 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & business update. Highlights: progress in clinical programmes, funding secured till 2025. Key focus on SARA, OBA, COVA, OBA, and MYODA programs

Financial Results Biophytis 2023 Funding Clinical Programmes
PRESS RELEASE

published on 04/08/2024 at 23:00, 2 years 7 months ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA phase 2 clinical study with BIO101 (20-hydroxyecdysone) for obesity treatment, targeting muscle preservation and promising results. Clinical program expected to start mid-2024

Biophytis Obesity Treatment BIO101 OBA Phase 2 Muscle Preservation
PRESS RELEASE

published on 04/08/2024 at 23:00, 2 years 7 months ago

Medicure Reports Financial Results for Quarter and Year Ended December 31, 2023
Medicure Inc. reports results from operations for the quarter and year ended December 31, 2023. Net revenue, EBITDA, and financial highlights disclosed

Financial Results EBITDA Quarterly Report Medicure Inc. Revenue Analysis

Accesswire

Published on 11/11/2026 at 14:25, 42 minutes ago

Route1 Announces 2026 Annual Meeting Results
Published on 11/11/2026 at 14:00, 1 hour 7 minutes ago

PPX Mining Reports Callanquitas Operating Results for the First Nine Months of 2026
Published on 11/11/2026 at 14:00, 1 hour 7 minutes ago

NuRAN Wireless Board Approves Growth Strategy to Scale Recurring Revenue from 5,000+ Contracted Towers
Published on 11/11/2026 at 13:15, 1 hour 52 minutes ago

Amarc Extends 2026 Exploration Program at the Duke District: Initiates Drilling Program at Established Porphyry Copper-Gold Targets
Published on 11/11/2026 at 13:00, 2 hours 7 minutes ago

NiobiumX Mining Reports Results of Ground Radiometric Survey at Shipshaw, Maps Two Distinct Radiometric Signatures Across the Core Claims, and Moves to a High-Resolution Airborne Survey of the Full 2,686-Hectare Package

View all ACCESSWIRE

EQS Group

Published on 11/11/2026 at 14:36, 30 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 11/11/2026 at 14:36, 31 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DCC plc
Published on 11/11/2026 at 14:35, 32 minutes ago

Form 8.3 - The Vanguard Group, Inc.: SEGRO plc
Published on 11/11/2026 at 14:34, 33 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Published on 11/11/2026 at 13:13, 1 hour 54 minutes ago

Elmos Semiconductor SE and AGIBOT showcase Humanoid Robotics at electronica 2026

Les Echos

Published on 11/10/2026 at 17:31, 21 hours 35 minutes ago

CNP Assurances SA announces the success of the issuance of a €500 million Tier 2 subordinated bond.
Published on 11/10/2026 at 14:00, 1 day 1 hour ago

Guillemot Corporation S.A. | Weekly report share buyback from November 2 to November 6, 2026
Published on 11/10/2026 at 11:02, 1 day 4 hours ago

Statement about the number of shares composing the share capital and the number of voting rights as of October 31, 2026
Published on 11/10/2026 at 07:00, 1 day 8 hours ago

bioMérieux receives U.S. FDA 510(k) Clearance and IVDR CE marking for VITEK® PRO, its new automated ID/AST instrument to support the fight against antimicrobial resistance
Published on 11/09/2026 at 18:30, 1 day 20 hours ago

Air Liquide has successfully issued a CHF 390 million multi-tranche bond

View all LES ECHOS COMFI WIRE